Sign In
Buy QURE
$29.88
+3.12 (+11.66%)
At Close: Jun 03, 2026
UniQure: Leading Gene Therapy Company
09:24am, Saturday, 06'th Nov 2021
QURE is a leader in gene therapy, and has the first commercially licensed gene therapy manufacturing facility. Utilizing their industry leading technology, they are developing treatments and cures for
What's Next For UniQure Stock After A 10% Rise In A Month?
09:15am, Thursday, 04'th Nov 2021
The recent rise can be attributed to its Q3 loss of $0.79 per share, which was better than the consensus estimate of $1.05 loss per share.
uniQure Announces Presentations at the Annual Meeting of The European Society of Gene and Cell Therapy (ESGCT)
07:05am, Tuesday, 19'th Oct 2021
Oral Presentation to Highlight AMT-191 for Fabry Disease Oral Presentation to Highlight AMT-191 for Fabry Disease
uniQure to Participate in Multiple Upcoming Industry Conferences in October
07:05am, Thursday, 30'th Sep 2021
LEXINGTON, Mass. and AMSTERDAM, Sept. 30, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs
Director Of Uniqure Sold $164.75 Thousand In Stock
12:49pm, Wednesday, 22'nd Sep 2021
Robert Gut, Director at Uniqure (NASDAQ:QURE), made a large insider sell on September 21, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission
uniQure to Participate in Multiple Upcoming Industry Conferences in September
07:05am, Tuesday, 07'th Sep 2021
LEXINGTON, Mass. and AMSTERDAM, Sept. 07, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs
~ No Significant Safety Concerns Observed Across a Total of 14 Completed Procedures ~
UniQure (QURE) Q2 Earnings and Revenues Top Estimates
10:00am, Monday, 26'th Jul 2021
uniQure (QURE) delivered earnings and revenue surprises of 198.60% and 118.14%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
uniQure Announces Second Quarter 2021 Financial Results and Highlights Recent Company Progress
07:05am, Monday, 26'th Jul 2021
~ Expanded gene therapy pipeline with four new research programs and announced acquisition of Corlieve Therapeutics ~
Late-Stage Clinical Study Readouts Biotech Investors Should Watch
02:04pm, Sunday, 11'th Jul 2021
Several drugmakers have important clinical trial updates on the way.
uniQure Announces Presentations at Upcoming International Society on Thrombosis and Haemostasis (ISTH) Virtual Congress
09:00am, Friday, 02'nd Jul 2021
LEXINGTON, Mass. and AMSTERDAM, The Netherlands, July 02, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with seve
What's Next For uniQure Stock After A 13% Drop Last Week?
07:30am, Friday, 25'th Jun 2021
The stock price of uniQure stock, a gene therapy company, has seen a a large 13% drop over the last five trading days. The company recently announced that the U.S. FDA has asked for eighteen months of
One Year Following Single Administration, UniQure's Hemophilia B Gene Therapy Candidate Shows Sustained Increase In Factor IX Levels
02:49pm, Tuesday, 22'nd Jun 2021
UniQure N.V. (NASDAQ: QURE) has announced 52-week data from its Phase 3 HOPE-B gene therapy trial of etranacogene dezaparvovec to treat hemophilia B.
UniQure Expands Gene Therapies Pipeline For Neurological Disorders With Corlieve Acquisition
12:47pm, Tuesday, 22'nd Jun 2021
UniQure N.V. (NASDAQ: QURE) has agreed to acquire Corlieve Therapeutics and its lead program for temporal lobe epilepsy (TLE), the most common form of focal epilepsy.
uniQure to Acquire Corlieve Therapeutics and Advance its Gene Therapy Program to Treat Temporal Lobe Epilepsy (TLE)
11:31am, Tuesday, 22'nd Jun 2021
~ Expands uniQure's Pipeline of Innovative Gene Therapies to Treat Neurological Disorders ~
